摘要
目的:探讨阿托伐他汀防再狭窄效应与促内皮生长作用最强的细胞因子——血管内皮生长因子(VEGF)血清浓度的相关性。方法:24只健康SD大鼠均分为假手术组、模型组与阿托伐他汀组,后两组行颈总动脉球囊损伤造模,损伤前及1周后分别测VEGF血清浓度,4周后观察再狭窄程度。结果:(1)模型组与阿托伐他汀干预组1周后VEGF血清浓度均显著升高,其中阿托伐他汀干预组VEGF增幅高于模型组;(2)阿托伐他汀干预组VEGF增幅与再狭窄程度呈线性负相关。结论:他汀类药物防治再狭窄的机制可能涉及促泌VEGF从而加速内皮修复。
Objective： Endothelial injury has been recognized a trigger point for the formation of restenosis, and reendothelialization is presumed to be the next target for restenosis preventing. Based on this, statins, the dassic restenosis preventing drugs, were supposed to prevent restenosis via promoting vascular endothelial growth factor （VEGF） secretion and accordingly accelerating reendothelialization. To test this hypothesis, this artide investigated the relationship between atrovastatin＇s beneficial effects on restenosis and serum VEGF concentration. Methods： 24 SD rats were equally divided into sham operation group, model group and atrovastatin group. In the latter two groups each rat＇s left common carotis was injured by balloon. Before and 1 week after balloon injury, serum VEGF levels were detected, and 4 weeks after balloon injury, the restenosis ratio of each subject was measured. Results： （1）Rat serum VEGF level significantly increased 1 week after balloon injury both in model group and in atrovastatin group, and the latter＇s was higher than the former＇s. （2） The growing rate of VEGF in atrovastatin group had linearly negative correlation with the degree of restenosis. Conclusions： The mechanism of statins in the prevention and treatment of restenosis might be related to promoting the secretion of VEGF, thus accelerating reendothelialization.
出处
《现代生物医学进展》
CAS
2007年第7期1005-1006,988,共3页
Progress in Modern Biomedicine
